Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer.
10.3779/j.issn.1009-3419.2025.106.10
- Author:
Liyan ZHAO
;
Kejing TANG
- Collective Name:Expert Consensus Working Group on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer;Lung Cancer Professional Committee of Guangdong Medical Women’s Association
- Publication Type:Consensus Development Conference
- Keywords:
Adverse drug reaction monitoring;
Efficacy monitoring;
Lung neoplasms;
Rational use of drugs;
Small molecule targeted therapeutic drugs
- MeSH:
Humans;
Lung Neoplasms/drug therapy*;
Antineoplastic Agents/adverse effects*;
Consensus;
Molecular Targeted Therapy;
Drug Monitoring;
Small Molecule Libraries/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2025;28(4):245-255
- CountryChina
- Language:Chinese
-
Abstract:
The application of small molecule targeted drugs for lung cancer has significantly improved the survival of lung cancer patients. However, these drugs have a wide variety of types, fast development and market launch of new drugs, complex adverse reactions, and are mostly used at home, which increases the risk of irrational drug use. At the same time, insufficient monitoring of efficacy and safety is also prone to occur, ultimately affecting treatment outcomes. This consensus focuses on 43 small molecule targeted drugs or combinations for lung cancer, providing standardized recommendations for rational drug use and monitoring of efficacy/adverse reactions in clinical practice. The recommendations are regarding drug selection, dosage adjustment, efficacy monitoring, adverse reaction monitoring, and improvement of patient compliance. This consensus aims to improve the rational use and efficacy/safety monitoring quality of small molecule targeted drugs for lung cancer, ensure the effectiveness and safety of drug treatment, prolong the survival of lung cancer patients and improve their quality of life.
.
